Flecainide to Prevent Atrial Arrhythmia after Patent Foramen Ovale Closure, the AFLOAT Study: A Randomized Clinical Trial.
Marie Hauguel-MoreauRoxana MehranClaire DauphinVincent AuffretJen-Michel ClercEloi MarijonMeyer ElbazPhilippe AldebertFarzin BeyguiWissam Abi KhalilAntoine Da CostaJean-Christophe MaciaSimon ElhadadGuillaume CaylaXavier IriartMikael LaredoThomas RollandYassine TemmarMaria Elisabeta GheorghiuDelphine BrugierJohanne SilvainNadjib HammoudiGuillaume DuthoitAbdourahmane DialloEric VicautGilles Montalescotnull nullPublished in: Circulation (2024)
In the first 6 months following successful PFO closure, AA (≥30s) occurred in 28.5% of cases, mostly in the first month after the procedure. Flecainide did not prevent AA after PFO closure.